COMPANY PROFILE
Euticals Spa is a privately owned company where shareholders are managers and insitutional investors.
Euticals plays a leader role in the MANUFACTURING of ACTIVE PHARMACEUTICAL INGREDIENTS (API’s) and in the CUSTOM SYNTHESIS field.
The company acts as a fully INTEGRATED API contract manufacturing organisation (API CMO):
- integrated in technologies: with its 4 plants, Euticals makes available to its customers a complete array of facilities, equipments and technologies;
- integrated in the quantities: with its R&D Centre and commercial scale plants, Euticals is able to supply active substances at any quantity, from grams to tons, always under cGMP compliance;
- integrated in the services: Euticals follows its customers in all steps of the development of a product, from process research to analytical development and process validation, to regulatory support up to the Dossier filing and updating.
THE HISTORY & THE PRESENT
THE HISTORY
1946 First Euticals establishment dates back to 1946 with the foundation of the Istituto Chemioterapico Italiano (ICI), a research pharmaceutical company based in Lodi, in the same site where Euticals SpA helds now its Headquarters offices.
1984 In 1984, following an ownership’s change, the ICI changed its name in Prime European Therapeuticals SpA, abbreviated in Euticals and focused its operations exclusively in the manufacture of bulk active ingredients.
2001 In this year, Euticals SpA acquired three more chemical plants in Casaletto Lodigiano, Rozzano and Varese, all located in north of Italy, creating a group of companies, the Euticals Group.
2008 In November 2008, all companies of the group merged in Euticals SpA and in the following December 2008 the company was acquired by an institutional investor, in a leveraged management buy out transaction.
… taken to the top quality standards”
THE PRESENT
With its FDA INSPECTED manufacturing plants and its Process Research and Development Centre located in Rozzano, Euticals SpA can provide its customers with top quality productions and services at competitive and sustainable prices.
Prices competitivness has now been strengthened by the new ownership through the implementation of strategic partnerships. Euticals main partners are top level chinese chemical manufacturer for raw materials and pharmaceutical intermediates.
All activities in Euticals are performed in compliance with all European and Italian regulations in terms of Safety.
HSE Policy and REACH
All new production projects and ongoing manufacturing processes are carefully analysed and controlled as per their impact on worker’s health, safety and environmental protection.
As per the latter, all 4 manufacturing sites have recently obtained IPPC authorizations, covering all emission issues:
Casaletto plant: No. 4427 of 4 May 2007
Lodi plant: AIA No.1576 of 21 Feb 2007
Rozzano plant:
Varese plant: No. 7926 of 18 Jul 2007
Furthermore, the recently introduced REACh regulation have seen Euticals SpA full commitment in the pre-registration phase. This phase has been duly and successfully completed for all substances handled by the company and relevant to the regulation.
Euticals SpA is then now working in close collaboration with the Aschimfarma lobby (Association of Italian Pharmaceutical Raw Materials Companies) in order to constantly monitor the development of the future steps of the REACh initiative so to successfully accomplish all the phases up to its conclusion in 2018.
Financials & Sales
